News | January 06, 2022
ENTOD Pharmaceuticals set to launch Molentod
It is the generic version of molnupiravir
It is the generic version of molnupiravir
The facility at the Andhra Pradesh Medtech Zone is expected to be completed by Dec 2022
DCGI approved the drug based on the review of clinical data
The drug will be marketed under the brand name Molnaflu
Trastuzumab is monoclonal antibody used to treat human epidermal growth factor receptor 2 positive (HER2+) breast cancer and metastatic gastric cancers
The study was performed independently by investigators at the US Food and Drug Administration (FDA), Center for Biologics Evaluation and Research
Immatics to receive upfront payment of US $ 150 million and additional milestone payments of up to US $ 770 million plus tiered double-digit royalties on net product sales
T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as the foundation for various investigational CAR-T therapies
Both companies will combine their expertise to channel real-world evidence toward ground-breaking new treatments in rare diseases
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
Subscribe To Our Newsletter & Stay Updated
